Biorestorative Therapies, Inc. (BRTX)
NASDAQ:BRTX
Top Page
BioRestorative Therapies
(NASDAQ:BRTX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.23
▼(-80.25% Downside)
Action:ReiteratedDate:03/27/26
The score is primarily weighed down by weak financial performance (very small revenue base, widening losses, and significant cash burn, alongside a sharply reduced equity cushion). Technicals are also bearish with the stock trading below major moving averages and negative MACD. The earnings call provides some offset via meaningful clinical/IP milestones and financing progress, but near-term fundamentals and revenue uncertainty keep the overall score low.
Positive Factors
Regulatory Progress - Fast Track
Fast Track designation for BRTX-100 increases structured regulatory engagement and can shorten the BLA pathway if trials succeed. This durable regulatory status reduces approval uncertainty, can accelerate development timelines, and enhances the program's attractiveness to partners and licensors over the next several quarters.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow indicates a structural cash burn that will require recurring external financing or material cost reductions. Over 2-6 months this constrains flexibility, increases dilution risk, and can force delays in trials or commercialization absent decisive revenue improvement or cost restructuring.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Progress - Fast Track
Fast Track designation for BRTX-100 increases structured regulatory engagement and can shorten the BLA pathway if trials succeed. This durable regulatory status reduces approval uncertainty, can accelerate development timelines, and enhances the program's attractiveness to partners and licensors over the next several quarters.
Read all positive factors
BioRestorative Therapies (BRTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.13M
Dividend YieldN/A
Average Volume (3M)8.17M
Price to Earnings (P/E)―
Beta (1Y)0.87
Revenue Growth1.70%
EPS Growth-111.67%
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.33
Shares Outstanding25,478,170
10 Day Avg. Volume2,443,532
30 Day Avg. Volume8,165,362
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)29.75
Price to Sales (P/S)29.50
P/FCF Ratio-0.97
Enterprise Value/Market Cap0.13
Enterprise Value/Revenue2.22
Enterprise Value/Gross Profit3.47
Enterprise Value/Ebitda-0.06
Forecast
1Y Price Target
$8.00Price Target Upside577.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.75
Revenue Forecast (FY)$1.90M
BioRestorative Therapies Business Overview & Revenue Model
Company Description
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs...
How the Company Makes Money
null...
BioRestorative Therapies Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 20, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant milestones in the company's clinical and commercial development, such as the Fast Track designation for BRTX-100 and a new patent for ThermoStem. However, these were counterbalanced by a sharp revenue decline and increased net loss compared to the previous year. Despite the financial setbacks, the overall sentiment is cautiously optimistic with strategic developments and a strengthened financial position.Positive Updates
Fast Track Designation for BRTX-100
The BRTX-100 program for chronic lumbar disc disease was granted Fast Track designation by the FDA, a major milestone that enables closer collaboration with the FDA for potential accelerated Biologic License Application (BLA) approval.
Negative Updates
Significant Revenue Decline
Third-quarter 2025 revenues were $11,800, a significant decrease from $233,600 in Q3 2024, primarily due to the timing of orders for the developing biocosmeceutical revenue stream.
Read all updates
Q3-2025 Updates
Positive
Negative
Fast Track Designation for BRTX-100
The BRTX-100 program for chronic lumbar disc disease was granted Fast Track designation by the FDA, a major milestone that enables closer collaboration with the FDA for potential accelerated Biologic License Application (BLA) approval.
Read all positive updates
Company Guidance
In the third quarter of 2025, BioRestorative Therapies reported a mixed financial performance, with revenues significantly declining to approximately $11,800 from $233,600 in the same period of 2024, primarily due to timing in the biocosmeceutical revenue stream. The company reported a loss from operations of $3.7 million, up from $2.3 million in the previous year, and a net loss of $3 million or $0.33 per share, compared to a net loss of $1 million or $0.13 per share in 2024. Despite these financial challenges, BioRestorative Therapies ended the quarter with $4.5 million in cash, cash equivalents, and marketable securities, excluding $1.1 million from recent financing. On the clinical front, the company is advancing its Phase II BRTX-100 study for chronic lumbar disc disease, with enrollment nearing completion and a potential Type B FDA meeting anticipated. The company also highlighted substantial progress in its ThermoStem program targeting obesity, while continuing discussions for a potential licensing agreement. The biocosmeceuticals business shows promise, with strategic leadership changes and a focus on expanding distribution channels, although revenue guidance remains uncertain.BioRestorative Therapies Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
32
Negative
Cash Flow
21
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 359.70K | 401.00K | 145.80K | 119.80K | 46.00K |
| Gross Profit | 335.86K | 372.93K | 145.80K | 119.80K | 46.00K |
| EBITDA | -15.44M | -11.37M | -14.97M | -18.74M | -26.22M |
| Net Income | -14.24M | -8.98M | -10.42M | -13.22M | -44.30M |
Balance Sheet | |||||
| Total Assets | 4.08M | 12.28M | 12.61M | 16.43M | 22.45M |
| Cash, Cash Equivalents and Short-Term Investments | 2.95M | 10.73M | 11.07M | 14.75M | 21.03M |
| Total Debt | 0.00 | 0.00 | 162.32K | 301.64K | 670.70K |
| Total Liabilities | 3.72M | 3.75M | 2.61M | 6.14M | 856.50K |
| Stockholders Equity | 356.74K | 8.53M | 10.00M | 10.29M | 21.60M |
Cash Flow | |||||
| Free Cash Flow | -10.91M | -8.34M | -6.60M | -6.35M | -3.36M |
| Operating Cash Flow | -10.79M | -8.23M | -6.43M | -5.91M | -3.33M |
| Investing Cash Flow | 8.90M | 514.53K | 3.25M | -13.40M | -30.66K |
| Financing Cash Flow | 2.85M | 7.38M | 2.35M | 0.00 | 21.32M |
BioRestorative Therapies Technical Analysis
Negative
1.18
Price Trends
0.40
Negative
0.77
Negative
1.16
Negative
Market Momentum
-0.04
Negative
37.48
Neutral
21.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRTX, the sentiment is Negative. The current price of 1.18 is above the 20-day moving average (MA) of 0.27, above the 50-day MA of 0.40, and above the 200-day MA of 1.16, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 37.48 is Neutral, neither overbought nor oversold. The STOCH value of 21.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BRTX.
BioRestorative Therapies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $29.18M | -1.88 | >-0.01% | ― | -12.99% | -13.67% | |
48 Neutral | $17.23M | -1.14 | -94.94% | ― | ― | 49.10% | |
46 Neutral | $40.06M | -0.71 | -80.00% | ― | ― | 9.63% | |
44 Neutral | $6.13M | -0.82 | -420.31% | ― | 1.70% | -111.67% | |
43 Neutral | $11.70M | -0.59 | -248.91% | ― | ― | 79.31% | |
42 Neutral | $21.25M | -0.09 | 0.02% | ― | ― | ― |
* Healthcare Sector Average
BRTX
BioRestorative Therapies
0.24
-1.54
-86.52%
CLRB
Cellectar Biosciences
2.76
-6.08
-68.78%
MRKR
Marker Therapeutics
1.75
0.65
59.09%
COCP
Cocrystal Pharma
1.25
-0.08
-6.02%
SNSE
Sensei Biotherapeutics
29.89
22.21
289.19%
AEON
AEON Biopharma
0.84
0.43
104.88%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.